Free Trial
NASDAQ:CUE

Cue Biopharma (CUE) Stock Price, News & Analysis

Cue Biopharma logo
$0.71 -0.08 (-10.01%)
As of 01:13 PM Eastern

About Cue Biopharma Stock (NASDAQ:CUE)

Key Stats

Today's Range
$0.71
$0.80
50-Day Range
$0.75
$1.49
52-Week Range
$0.45
$2.26
Volume
80,337 shs
Average Volume
444,010 shs
Market Capitalization
$45.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.75
Consensus Rating
Buy

Company Overview

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Remove Ads

Cue Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
90th Percentile Overall Score

CUE MarketRank™: 

Cue Biopharma scored higher than 90% of companies evaluated by MarketBeat, and ranked 69th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cue Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Cue Biopharma has received no research coverage in the past 90 days.

  • Read more about Cue Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Cue Biopharma are expected to grow in the coming year, from ($0.76) to ($0.55) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cue Biopharma is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cue Biopharma is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cue Biopharma has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Cue Biopharma's valuation and earnings.
  • Percentage of Shares Shorted

    1.55% of the float of Cue Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Cue Biopharma has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cue Biopharma has recently decreased by 9.98%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Cue Biopharma does not currently pay a dividend.

  • Dividend Growth

    Cue Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.55% of the float of Cue Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Cue Biopharma has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cue Biopharma has recently decreased by 9.98%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Cue Biopharma has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Cue Biopharma this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for CUE on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Cue Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cue Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.26% of the stock of Cue Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 35.04% of the stock of Cue Biopharma is held by institutions.

  • Read more about Cue Biopharma's insider trading history.
Receive CUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cue Biopharma and its competitors with MarketBeat's FREE daily newsletter.

CUE Stock News Headlines

Cue Biopharma reports Q4 EPS (13c), consensus (14c)
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
Artiva expands Board with appointment of Dan Baker, M.D
See More Headlines

CUE Stock Analysis - Frequently Asked Questions

Cue Biopharma's stock was trading at $1.09 on January 1st, 2025. Since then, CUE stock has decreased by 35.3% and is now trading at $0.7050.
View the best growth stocks for 2025 here
.

Cue Biopharma, Inc. (NASDAQ:CUE) released its quarterly earnings data on Friday, March, 28th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.01. The firm had revenue of $1.80 million for the quarter, compared to the consensus estimate of $1.70 million. Cue Biopharma had a negative net margin of 468.02% and a negative trailing twelve-month return on equity of 156.38%.

Shares of CUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cue Biopharma investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Walmart (WMT).

Company Calendar

Last Earnings
3/28/2025
Today
4/03/2025
Next Earnings (Estimated)
4/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CUE
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.75
High Stock Price Target
$10.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+501.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-50,730,000.00
Net Margins
-468.02%
Pretax Margin
-468.02%

Debt

Sales & Book Value

Annual Sales
$9.53 million
Price / Cash Flow
N/A
Book Value
$0.82 per share
Price / Book
0.96

Miscellaneous

Free Float
55,583,000
Market Cap
$50.05 million
Optionable
Optionable
Beta
1.88
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:CUE) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners